NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Non-Viral TCR Gene Therapy

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Endocrine/Neuroendocrine
Gastrointestinal/Genitourinary Cancers
Ovarian Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Aldesleukin
Biological: Sleeping Beauty Transposed PBL

First Posted Date: 2019-09-25

Last Posted Date: 2024-03-12

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04102436

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Biological: Durvalumab
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed Disodium

First Posted Date: 2019-09-17

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 660

Registration Number: NCT04092283

Locations: 🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸
Essentia Health - Ely Clinic, Ely, Minnesota, United States
🇺🇸
James J Peters VA Medical Center, Bronx, New York, United States

and more 831 locations

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Phase 1

Active, not recruiting

Conditions: Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Recurrent Ovarian Endometrioid Adenocarcinoma
Endometrial High Grade Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Ovarian High Grade Serous Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Ovarian Carcinosarcoma
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Peposertib

First Posted Date: 2019-09-17

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT04092270

Locations: 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Bone
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Other: Electronic Health Record Review
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Radiation: Radium Ra 223 Dichloride
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2019-09-16

Last Posted Date: 2025-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT04090398

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 27 locations

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1

Recruiting

Conditions: Neuroendocrine Neoplasms
Gastroenteropancreatico Tumors
Neuroendocrine Tumors

Interventions: Drug: Lu-177-DOTATATE
Drug: Olaparib
Diagnostic Test: Ga dotatate scanning
Diagnostic Test: FDG-PET scanning
Drug: Amino Acid infusion

First Posted Date: 2019-09-11

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT04086485

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2

Active, not recruiting

Conditions: Metastatic Large Cell Neuroendocrine Carcinoma
Metastatic Neuroendocrine Carcinoma
Metastatic Small Cell Neuroendocrine Carcinoma
Metastatic Neuroendocrine Neoplasm

Interventions: Drug: Cabozantinib S-malate
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2019-09-06

Last Posted Date: 2025-03-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT04079712

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 43 locations

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Von Hippel-Lindau Disease
VHL Pancreatic Neuroendocrine Tumors

Interventions: Drug: 68-Gallium DOTATATE

First Posted Date: 2019-08-29

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 740

Registration Number: NCT04074135

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Phase 1

Recruiting

Conditions: Locally Advanced Malignant Solid Neoplasm
Locally Advanced Unresectable Cholangiocarcinoma
Locally Advanced Unresectable Gallbladder Carcinoma
Locally Advanced Unresectable Malignant Solid Neoplasm
Metastatic Cholangiocarcinoma
Metastatic Gallbladder Carcinoma
Metastatic Malignant Solid Neoplasm
Stage III Gallbladder Cancer AJCC v8
Stage IV Gallbladder Cancer AJCC v8
Unresectable Malignant Solid Neoplasm

Interventions: Drug: Avelumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Radiation: Hypofractionated Radiation Therapy
Drug: Peposertib

First Posted Date: 2019-08-28

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 103

Registration Number: NCT04068194

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 41 locations

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Carcinoma
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Lymph Nodes
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Avelumab
Procedure: Bone Scan
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Other: Questionnaire Administration
Radiation: Radium Ra 223 Dichloride
Drug: Peposertib

First Posted Date: 2019-08-28

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT04071236

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 27 locations

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2

Recruiting

Conditions: Advanced Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Collecting Duct Carcinoma
Kidney Medullary Carcinoma
Metastatic Malignant Neoplasm in the Bone
Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Unclassified Renal Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radium Ra 223 Dichloride

First Posted Date: 2019-08-28

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 134

Registration Number: NCT04071223

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 43 locations

Home Terms & Conditions Privacy Policy